Century Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.11.

EBIT: As of FY2026 Q1, the actual value is USD -25.7 M.

Century Therapeutics, Inc. operates as a single reportable segment, meaning all financial metrics are presented on a company-wide basis .

Collaboration Revenue

Collaboration revenue for the three months ended March 31, 2026, was $0 million, a significant decrease from $109.2 million for the same period in 2025, representing a - $109.2 million change . This decrease was primarily due to the termination of the collaboration agreement with Bristol-Myers Squibb, effective March 12, 2025, which led to the recognition of the remaining transaction price in the first quarter of 2025 . No future collaboration revenues are expected from this agreement .

Operating Expenses

Total operating expenses decreased to $23.7 million for the three months ended March 31, 2026, from $35.0 million in the prior year, a - $11.3 million change . Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the three months ended March 31, 2026, down from $26.6 million for the same period in 2025, a decrease of - $9.5 million . This reduction was driven by a - $4.4 million decrease in personnel and related costs due to staff reduction, a - $1.9 million decrease in facility and other allocated costs following portfolio prioritization, and a - $2.0 million decrease in research and laboratory expenses due to reduced spending on CNTY-101 clinical trials . General and Administrative (G&A) Expenses: G&A expenses decreased to $6.6 million for the three months ended March 31, 2026, from $8.4 million in the prior year, a - $1.8 million change . This was mainly due to a reduction in personnel and the remeasurement of the contingent consideration liability, partially offset by an increase in facility and other allocated costs .

Income (Loss) from Operations

Income from operations shifted from a gain of $74.2 million for the three months ended March 31, 2025, to a loss of - $23.7 million for the same period in 2026, a - $97.9 million change .

Net Income (Loss)

Net income (loss) was - $21.6 million for the three months ended March 31, 2026, compared to a net income of $76.6 million for the three months ended March 31, 2025, resulting in a - $98.2 million change .

Interest Income

Interest income decreased to $2.0 million for the three months ended March 31, 2026, from $2.4 million for the same period in 2025, a - $0.4 million change .

Cash Flows

• Net Cash Used in Operating Activities: Net cash used in operating activities was - $25.3 million for the three months ended March 31, 2026, an improvement from - $34.6 million used in the prior year period .
• Net Cash Used in Investing Activities: Net cash used in investing activities was - $112.6 million for the three months ended March 31, 2026, compared to $27.9 million provided by investing activities for the same period in 2025 . The 2026 figure included - $140.7 million in acquisition of fixed maturity securities, partially offset by $28.7 million from the sale of fixed maturity securities .
• Net Cash Provided by Financing Activities: Net cash provided by financing activities significantly increased to $126.6 million for the three months ended March 31, 2026, from $0.1 million in the prior year . This increase was primarily driven by $126.4 million in net proceeds from the 2026 Private Placement .

Liquidity and Capital Resources

As of March 31, 2026, Century Therapeutics, Inc. had cash, cash equivalents, and investments totaling $217.0 million . The company’s accumulated deficit stood at - $813.6 million as of the same date .

Outlook and Strategy

Century Therapeutics, Inc. expects its current cash, cash equivalents, and investments to fund operations and capital expenditures into the first quarter of 2029 . The company anticipates increased future expenses and operating losses as it advances its iPSC cell therapy platforms, progresses product candidates through preclinical and clinical development, and expands manufacturing capabilities . Specifically, an Investigational New Drug (IND) application for CNTY-813 is expected in the fourth quarter of 2026, and clinical studies for CNTY-308 are planned to begin in 2026 .